Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07452432 | Korean Prospective Upper Tract Urothelial Carcinoma Cohort | recruiting | — | 300 | Samsung Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05321316 |
| Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma |
| recruiting |
| N/A |
| 20 |
| Peking University Cancer Hospital & InstituteOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT06699602 | A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST) | recruiting | Phase 2 | 72 | University of OklahomaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07441499 | Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma | recruiting | — | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma(IMPROEV) | recruiting | Phase 2 | 97 | Fox Chase Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 47 | University of California, San FranciscoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05641935 | Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation | recruiting | Phase 2 | 210 | john eisenbreyOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06138561 | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | recruiting | — | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07395037 | A Study of Ward Admissions for Haematuria(WASHOUT) | recruiting | — | 1,050 | British Urology Researchers in Surgical TrainingOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07183319 | Circulating Tumor DNA Response In Urothelial Cancer | recruiting | Phase 2 | 30 | University of OklahomaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06583070 | SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer(COSTAR) | recruiting | — | 300 | Peking University First HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06234605 | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 80 | HiberCell, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06726421 | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)(STROKER) | recruiting | Phase 3 | 252 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339761 | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study(SPICE) | recruiting | N/A | 30 | University of AarhusOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339878 | Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma(FLORAL) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04299646 | A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases(GETUG-StORM-01) | recruiting | Phase 2 | 77 | Centre Francois BaclesseOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07334314 | Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs(OUAF) | recruiting | — | 340 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326280 | The Cold Ischemia Robot-assisted Partial Nephrectomy | recruiting | N/A | 310 | Sun Yat-sen UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07314723 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | recruiting | Phase 2 | 90 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06120374 | Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC | recruiting | — | 178 | Peking University First HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301827 | Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma | recruiting | N/A | 66 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07077447 | The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract(EuroCUT) | recruiting | — | 2,500 | Zealand University HospitalOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT07171190 | Targeted Abdominal CT in Conjunction With Lung Cancer Screening(TACTICAL1) | recruiting | N/A | 6,272 | University of CambridgeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294859 | Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy | recruiting | — | 285 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06263153 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | recruiting | Phase 2 | 24 | Yuanquan YangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06210490 | A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery | recruiting | Phase 2 | 60 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05917106 | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) | recruiting | — | 450 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05912816 | Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | recruiting | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06676527 | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma | recruiting | — | 39 | Jinling Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07240610 | Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma(AURICRE) | recruiting | — | 145 | Zhe ChenOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04974671 | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04989959 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 35 | Orhan Kemal OzOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05387863 | Decision Aid (DA) for Renal Patients | recruiting | N/A | 40 | NYU Langone HealthOTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2026source: clinicaltrials